Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | PRNP | P04156 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | HPGD | P15428 | 5/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2296843 | 0.92 | MAPT (0.47) | MEN1KMT2AMAPTPRNPKDM4E | |
| SCHEMBL3535937 | 0.91 | KDM4E (0.48) | MEN1KMT2AMAPTPRNPKDM4E | |
| SCHEMBL2301421 | 0.91 | ALOX5 (0.57) | MEN1KMT2AMAPTPRNPKDM4E | |
| SCHEMBL16509667 | 0.89 | MAPT (0.50) | MEN1KMT2AMAPTPRNPKDM4E | |
| SCHEMBL6118713 | 0.88 | KDM4E (0.44) | MEN1KMT2AMAPTPRNPKDM4E | |
| SCHEMBL2297483 | 0.87 | PTGS2 (0.50) | MEN1KMT2AMAPTPRNPKDM4E | |
| SCHEMBL2301063 | 0.86 | ALOX5 (0.57) | MEN1KMT2AMAPTKDM4EALOX5 | |
| SCHEMBL6119913 | 0.85 | KDM4E (0.46) | MEN1KMT2AMAPTPRNPKDM4E | |
| SCHEMBL3398857 | 0.84 | PTGS2 (0.51) | MEN1KMT2AMAPTPRNPKDM4E | |
| SCHEMBL2299408 | 0.83 | MEN1 (0.49) | MEN1KMT2AMAPTPRNPKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2632261-B1 | INHIBITORS OF HEPATITIS C VIRUS | PRESIDIO PHARMACEUTICALS INC (US) | 2016-07-13 | — | — | EP | disclosed |
| US-9309260-B2 | Inhibitors of hepatitis C virus | PRESIDIO PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9309260-B2 | Inhibitors of hepatitis C virus | PRESIDIO PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9085587-B2 | Inhibitors of hepatitis C virus | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-9085587-B2 | Inhibitors of hepatitis C virus | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20130302282-A1 | Inhibitors of Hepatitis C Virus | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130302282-A1 | Inhibitors of Hepatitis C Virus | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20120276051-A1 | INHIBITORS OF HEPATITIS C VIRUS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120276051-A1 | INHIBITORS OF HEPATITIS C VIRUS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120251497-A1 | INHIBITORS OF HEPATITIS C VIRUS | PRESIDIO PHARMACEUTICALS, INC. | 2012-10-04 | — | — | US | disclosed |
| US-20120251497-A1 | INHIBITORS OF HEPATITIS C VIRUS | PRESIDIO PHARMACEUTICALS, INC. | 2012-10-04 | — | — | US | disclosed |
| WO-2012067663-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012058125-A1 | INHIBITORS OF HEPATITIS C VIRUS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | WO | disclosed |
| WO-2011103063-A1 | THERAPEUTIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120276051-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, LIPC, HCCS | MEN1 4815/4885KMT2A 4092/4885MAPT 3566/4885 |
| US-20130302282-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, LIPC, HCCS | MEN1 4815/4885KMT2A 4092/4885MAPT 3566/4885 |
| US-20120251497-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, LIPC, HCCS | MEN1 4815/4885KMT2A 4092/4885MAPT 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.